<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093001</url>
  </required_header>
  <id_info>
    <org_study_id>08-008690</org_study_id>
    <nct_id>NCT01093001</nct_id>
  </id_info>
  <brief_title>Tricuspid Regurgitation Study</brief_title>
  <official_title>The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of cardiac pacing leads on tricuspid regurgitation is unclear. This study will
      determine whether using a smaller diameter leads and an alternate position in the ventricle,
      the proximal septum, will reduce tricuspid regurgitation than larger leads placed in the
      apex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leads are commonly placed in the right ventricular apex. It is not known whether placing
      similar leads higher on the septum where there will be less redundancy or pressure on the
      septal leaflet will change the extent and severity of tricuspid regurgitation following
      pacemaker/ICD implantation. Data has shown that right ventricular pacing can give rise to
      right ventricular dysfunction, which in turn may give rise to enlargement of the right
      ventricle and cause tricuspid regurgitation.

      The study will answer the clinically relevant questions on device lead-related tricuspid
      regurgitation.

      This study is a single center prospective study at the Mayo Clinic, Rochester. The study will
      enroll 200 eligible subjects and follow for 12 months. 50 pacemaker subjects will be
      randomized to right ventricular apex pacing 50 pacemaker subjects will be randomized to right
      ventricular septum pacing 50 pacemaker subjects will be randomized to left ventricular pacing
      via coronary sinus 50 ICD subjects will be enrolled with right ventricular apex pacing.

      A baseline heart failure assessment and Two Dimensional echocardiography will be performed
      before device implant.

      A Two Dimensional echo will be performed 24 hours after device implant. If significance TR is
      present a Three Dimensional echo will be performed. At 12 months post implant heart failure
      assessment and Two Dimensional echo will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Tricuspid Regurgitation using smaller diameter lead and placing the lead on the proximal septum.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular lead placement will be associated with least amount of TR because of avoiding crossing the tricuspid valve and by virtue of relatively more synchronous ventricular contractions.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Right Ventricular Dysfunction</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Lead size</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The pacemaker lead will be &lt; or = to 7Fr. The ICD lead will be 9 Fr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV Lead position</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients will be randomized to RV apex lead placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-Septum Lead position</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients will be randomized to RV mid-septum lead placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS lead position</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients will have lead placed in the CS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echo</intervention_name>
    <description>Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.</description>
    <arm_group_label>Lead size</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echo</intervention_name>
    <description>Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation</description>
    <arm_group_label>RV Lead position</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echo</intervention_name>
    <description>Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.</description>
    <arm_group_label>Mid-Septum Lead position</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echo</intervention_name>
    <description>Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.</description>
    <arm_group_label>CS lead position</arm_group_label>
    <other_name>Medtronic Starfix lead</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of either sex

               -  Patient is recommended to receive a pacemaker or an ICD

               -  Provide informed consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Congenital heart disease

          -  Pre-existing moderate or severe TR

          -  An existing pacemaker or defibrillator

          -  Pulmonary hypertension

          -  Pacemaker dependence

          -  Unable to give informed consent

          -  Not feasible for patient to be followed up at Mayo Clinic

          -  Acute myocardial infarction within 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Mei Cha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>1. Lin G, Nishimura R, Connolly H, Dearani J, Sundt T, Hayes D: Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. JACC 2005; 45:1672-1675. 2. Leibowitz D, Rosenheck S, Pollak A, Geist M, Gilon D: Transvenous pacemaker leads do not worsen tricuspid regurgitation: a prospective echocardiographic study. Arrhythmias, Electrophysiology and Electrocardiography 2000; 93:74-77. 3. Kucukarslan N, Kirilmaz A, Ulusoy E, Yokusoglu M, Gramatnikovski N, Ozal E, Tatar H: Tricuspid insufficiency does not increase early after permanent implantation of pacemaker leads. J Card Surg 2006; 21:391-394. 4. Wilkoff B, Invesigators DT: The dual chamber and WI implantable defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials. Cardiac Electrophysiol Review 2004; 7:468-472.</citation>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yong-Mei Cha</investigator_full_name>
    <investigator_title>Cardiovascular Division</investigator_title>
  </responsible_party>
  <keyword>Reduce Tricuspid Regurgitation</keyword>
  <keyword>Reduce Right Ventricular pacing</keyword>
  <keyword>Lead position</keyword>
  <keyword>Lead size</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

